An additional fee is required to attend this short course. To register, visit www.aaps.org/AMRegister
Infectious diseases caused by viral or bacterial pathogens are a major cause of death and morbidity worldwide, contributing to approximately 25% of global mortality, and pose a critical health care challenge. Treatment and prevention has become a pharmaceutical product development focus in response to global unmet needs. The number of infectious disease outbreaks as well as the number of kinds of diseases has significantly increased since 1980. The 2014 Ebola outbreak in West Africa and recent implications of the Zika virus raised awareness of the global burden of infectious diseases. Reports of a significant rise in sexually transmitted diseases combined with U.S. statistics such as 50,000 new cases of HIV, 36,000 new cases of Hepatitis B or C, and 36,000 annual deaths from influenza has driven a rise in interest to develop safe and effective pharmaceutical products for treatment or prevention of infectious diseases. Recently, a number of innovative drug delivery approaches have been applied in this area, which has become of higher interest to the pharmaceutical market.
•Understand progress in nanomedicine for HIV/AIDS prevention
•Know recent advances on formulation for respiratory route to treat tuberculosis
•Know emerging formulation to prevent future Ebola outbreak
•Discuss alternative formulation for HIV/AIDS prevention (e.g. Thin Film)
•Learn from progress on alternative formulation for Hepatitis C (Nanoemulsion)